Covid-19 roundup: Sanofi promises to bring recombinant vaccine capacity to 1B+ while scaling up mRNA manufacturing
Sanofi believes it’s lined up two of the best shots at a Covid-19 vaccine by teaming up with GlaxoSmithKline on the older recombinant approach and enlisting Translate Bio’s splashy mRNA tech. And now the pharma giant is bringing its manufacturing capacity up to match that.
Building on a previous promise to supply 100 to 600 million doses of a baculovirus recombinant vaccine, Sanofi has set a goal to go beyond 1 billion doses within a year — echoing similar ambitions by its Big Pharma brethren J&J. On the mRNA front, Sanofi said its partners can scale up to manufacture 90 to 360 million doses by the first quarter of 2021.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.